Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer

NCT02953860 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT02953860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02953860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Fulvestrant Plus Enzalutamide in ER+/Her2- Advanced Breast Cancer
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Completed
Start date
July 6, 2017
Completion date
April 10, 2020
Enrollment
32 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer